Clusterin Expression in Colorectal Carcinomas.

biomarker clusterin colorectal cancer personalized medicine targeted treatment tumorigenesis

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
27 Sep 2023
Historique:
received: 16 08 2023
revised: 25 09 2023
accepted: 26 09 2023
medline: 23 10 2023
pubmed: 14 10 2023
entrez: 14 10 2023
Statut: epublish

Résumé

Colorectal cancer is the third most diagnosed cancer, behind only breast and lung cancer. In terms of overall mortality, it ranks second due to, among other factors, problems with screening programs, which means that one of the factors that directly impacts survival and treatment success is early detection of the disease. Clusterin (CLU) is a molecular chaperone that has been linked to tumorigenesis, cancer progression and resistance to anticancer treatments, which has made it a promising drug target. However, it is still necessary to continue this line of research and to adjust the situations in which its use is more favorable. The aim of this paper is to review the current genetic knowledge on the role of CLU in tumorigenesis and cancer progression in general, and discuss its possible use as a therapeutic target in colorectal cancer.

Identifiants

pubmed: 37834086
pii: ijms241914641
doi: 10.3390/ijms241914641
pmc: PMC10572822
pii:
doi:

Substances chimiques

Clusterin 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Expert Opin Ther Targets. 2023 Apr-May;27(4-5):305-324
pubmed: 37243489
Front Neurosci. 2019 Feb 28;13:164
pubmed: 30872998
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
J Mol Endocrinol. 1994 Aug;13(1):69-76
pubmed: 7999255
Cancer. 2005 Jan 15;103(2):277-83
pubmed: 15578711
Cancer Treat Rev. 2022 Feb;103:102325
pubmed: 34954486
Int J Biochem Cell Biol. 2002 Nov;34(11):1430-48
pubmed: 12200037
Biochim Biophys Acta. 2015 Aug;1852(8):1630-45
pubmed: 25917404
Pancreas. 2002 Oct;25(3):234-8
pubmed: 12370533
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):725-9
pubmed: 8421712
J Clin Med. 2020 Jan 02;9(1):
pubmed: 31906589
Ann Oncol. 2018 Oct 1;29(10):2061-2067
pubmed: 30412224
BMC Cancer. 2014 Nov 29;14:891
pubmed: 25432628
Clin Cancer Res. 2019 Dec 1;25(23):6899-6908
pubmed: 31263029
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Expert Rev Anticancer Ther. 2016 May;16(5):557-71
pubmed: 27010906
JAMA. 2021 Feb 16;325(7):669-685
pubmed: 33591350
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
J Clin Oncol. 2004 Apr 1;22(7):1209-14
pubmed: 15051767
J Clin Oncol. 2007 Apr 20;25(12):1539-44
pubmed: 17442997
Elife. 2019 Nov 18;8:
pubmed: 31738162
BMC Cancer. 2015 Feb 14;15:56
pubmed: 25884309
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6
pubmed: 10411935
Oncogene. 2002 Jun 20;21(27):4328-34
pubmed: 12082621
J Clin Oncol. 2022 Aug 20;40(24):2706-2715
pubmed: 35649231
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
J Gastrointest Cancer. 2012 Jun;43(2):305-13
pubmed: 21487682
Nature. 1986 May 15-21;321(6067):209-13
pubmed: 2423876
Nat Commun. 2018 Jul 23;9(1):2884
pubmed: 30038269
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Comput Math Methods Med. 2022 Oct 11;2022:9408839
pubmed: 36267311
Int J Environ Res Public Health. 2022 Mar 18;19(6):
pubmed: 35329320
Cancer. 2019 Dec 1;125(23):4139-4147
pubmed: 31433498
Sci Rep. 2023 Feb 15;13(1):2739
pubmed: 36792801
Mol Cancer Ther. 2004 Mar;3(3):223-32
pubmed: 15026542
N Engl J Med. 2008 Mar 13;358(11):1160-74
pubmed: 18337605
Rev Endocr Metab Disord. 2014 Mar;15(1):45-53
pubmed: 24097125
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Biochemistry. 1987 Jun 16;26(12):3297-303
pubmed: 3651384
Histopathology. 2007 Jan;50(1):113-30
pubmed: 17204026
J Natl Cancer Inst. 2019 Nov 1;111(11):1131-1141
pubmed: 31322663
Sci Rep. 2021 Jul 21;11(1):14838
pubmed: 34290294
J Exp Clin Cancer Res. 2003 Jun;22(2):223-8
pubmed: 12866572
Cancer Res. 2004 Sep 1;64(17):6174-82
pubmed: 15342402
Int J Biochem Cell Biol. 2012 Oct;44(10):1646-56
pubmed: 22571949
Oncogene. 2011 Sep 1;30(35):3745-54
pubmed: 21460853
Gastrointest Endosc Clin N Am. 2022 Apr;32(2):195-213
pubmed: 35361331
World J Gastroenterol. 2005 Nov 14;11(42):6694-700
pubmed: 16425368
CA Cancer J Clin. 2022 Jul;72(4):372-401
pubmed: 35472088
PLoS One. 2013 Sep 20;8(9):e75303
pubmed: 24073260
Cancer Res. 2018 Jan 1;78(1):7-14
pubmed: 29263151
Oncogene. 2001 Feb 8;20(6):739-47
pubmed: 11314007
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Gastroenterology. 2022 Mar;162(3):715-730.e3
pubmed: 34757143
Histopathology. 2013 Feb;62(3):367-86
pubmed: 23339363
Cochrane Database Syst Rev. 2017 Jun 27;6:CD007047
pubmed: 28654140
Clin Cancer Res. 2012 Nov 1;18(21):6023-31
pubmed: 22977191
Free Radic Res. 2006 Dec;40(12):1324-34
pubmed: 17090421
Mol Cancer. 2021 Nov 6;20(1):143
pubmed: 34742312
Cell Death Differ. 2005 Jan;12(1):101-4
pubmed: 15499376
Cell. 1990 Jun 1;61(5):759-67
pubmed: 2188735
Cancer. 2002 Sep 15;95(6):1199-205
pubmed: 12216085
Clin Biochem. 2020 Jan;75:62-69
pubmed: 31672651
Clin Cancer Res. 2017 Sep 15;23(18):5339-5348
pubmed: 28611198
Biochem J. 1997 Nov 15;328 ( Pt 1):45-50
pubmed: 9359832
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
Int J Cancer. 2014 Dec 1;135(11):2633-43
pubmed: 24752533
N Engl J Med. 2021 Jan 14;384(2):185-187
pubmed: 33497555
Genes Dev. 2021 Jun;35(11-12):787-820
pubmed: 34074695
Oncogene. 2004 Mar 25;23(13):2298-304
pubmed: 14755245
Prostate. 2002 Feb 15;50(3):179-88
pubmed: 11813210
J Comp Neurol. 1993 Aug 8;334(2):209-27
pubmed: 8366194
Biochem Biophys Res Commun. 2003 Nov 7;311(1):98-103
pubmed: 14575700
Front Immunol. 2020 Sep 18;11:1624
pubmed: 33042104
Oncogene. 2013 Apr 11;32(15):1933-42
pubmed: 22689054
Adv Cancer Res. 2009;105:45-61
pubmed: 19879422
Traffic. 2007 May;8(5):554-65
pubmed: 17451556
Molecules. 2020 Jan 31;25(3):
pubmed: 32023884
Histopathology. 2010 Jun;56(7):932-6
pubmed: 20497247
Tumour Biol. 2009;30(5-6):286-91
pubmed: 19940549
J Exp Clin Cancer Res. 2021 Apr 15;40(1):132
pubmed: 33858476
Lancet. 2014 Apr 26;383(9927):1490-1502
pubmed: 24225001
Int J Mol Sci. 2017 Jun 13;18(6):
pubmed: 28608814
Neoplasma. 2010;57(3):191-7
pubmed: 20353268
J Natl Cancer Inst. 2021 Oct 1;113(10):1386-1395
pubmed: 33734401
Adv Cancer Res. 2009;105:21-43
pubmed: 19879421
J Clin Oncol. 2019 Jan 1;37(1):33-43
pubmed: 30403572
Clin Cancer Res. 2010 Feb 15;16(4):1088-93
pubmed: 20145158
Nat Rev Dis Primers. 2015 Nov 05;1:15065
pubmed: 27189416
Mol Neurobiol. 2012 Apr;45(2):314-26
pubmed: 22274961
Urology. 2002 Jan;59(1):150-4
pubmed: 11796313
Am J Pathol. 2000 Aug;157(2):393-9
pubmed: 10934144
J Exp Med. 2014 Oct 20;211(11):2231-48
pubmed: 25245761
Adv Cancer Res. 2009;104:25-32
pubmed: 19878771
CA Cancer J Clin. 2023 May-Jun;73(3):233-254
pubmed: 36856579
Br J Cancer. 2011 Jun 28;105(1):58-64
pubmed: 21673685
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
CA Cancer J Clin. 2022 Sep;72(5):409-436
pubmed: 35736631
Bioengineered. 2019 Dec;10(1):229-239
pubmed: 31117872
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):381-388
pubmed: 28068245
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Adv Cancer Res. 2009;104:9-23
pubmed: 19878770
J Clin Oncol. 2011 Mar 1;29(7):884-9
pubmed: 21189384
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Arch Oral Biol. 1979;24(10-11):791-7
pubmed: 120733
Cancer Sci. 2009 Dec;100(12):2354-60
pubmed: 19793084
Dis Colon Rectum. 2018 May;61(5):554-560
pubmed: 29624549
J Biol Chem. 2003 Mar 28;278(13):11590-600
pubmed: 12551933
Biochem J. 2004 Aug 15;382(Pt 1):157-68
pubmed: 15139853
Gastrointest Endosc Clin N Am. 2022 Apr;32(2):177-194
pubmed: 35361330
Eur J Immunol. 2005 Dec;35(12):3561-9
pubmed: 16278812
Blood. 2000 Jul 15;96(2):398-404
pubmed: 10887098
Oncotarget. 2017 May 30;8(22):36728-36742
pubmed: 27888636
Adv Cancer Res. 2009;105:1-19
pubmed: 19879420
Int J Cancer. 2004 Jan 1;108(1):23-30
pubmed: 14618611
Br J Cancer. 2004 Nov 15;91(10):1842-50
pubmed: 15494717
J Invest Dermatol. 2005 Jun;124(6):1300-7
pubmed: 15955107
Discov Med. 2011 Feb;11(57):95-105
pubmed: 21356164
Front Immunol. 2021 Dec 15;12:784336
pubmed: 34975873
Nat Biotechnol. 2015 May;33(5):449-51
pubmed: 25965745
Biochemistry. 2000 Dec 26;39(51):15953-60
pubmed: 11123922
Gerontology. 2013;59(6):514-23
pubmed: 23689375
Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188500
pubmed: 33385484

Auteurs

Teresa Téllez (T)

Surgical Specialties, Biochemistry and Immunology Department, Faculty of Medicine, University of Málaga, 29010 Malaga, Spain.
Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS), Instituto de Investigación Biomédica de Málaga (IBIMA), 29590 Malaga, Spain.
Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Malaga, Spain.

Desirée Martin-García (D)

Surgical Specialties, Biochemistry and Immunology Department, Faculty of Medicine, University of Málaga, 29010 Malaga, Spain.
Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS), Instituto de Investigación Biomédica de Málaga (IBIMA), 29590 Malaga, Spain.
Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Malaga, Spain.
Research and Innovation Unit, Hospital Costa del Sol, 29602 Marbella, Spain.

Maximino Redondo (M)

Surgical Specialties, Biochemistry and Immunology Department, Faculty of Medicine, University of Málaga, 29010 Malaga, Spain.
Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS), Instituto de Investigación Biomédica de Málaga (IBIMA), 29590 Malaga, Spain.
Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Malaga, Spain.
Research and Innovation Unit, Hospital Costa del Sol, 29602 Marbella, Spain.

Marilina García-Aranda (M)

Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS), Instituto de Investigación Biomédica de Málaga (IBIMA), 29590 Malaga, Spain.
Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Malaga, Spain.
Research and Innovation Unit, Hospital Costa del Sol, 29602 Marbella, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH